The Effective and Tolerable Titration Scheme and Dosage in Children With Attention-deficit Hyperactivity Disorder Treated With OROS [osmotic-release oral syst]-Methylphenidate.

Trial Profile

The Effective and Tolerable Titration Scheme and Dosage in Children With Attention-deficit Hyperactivity Disorder Treated With OROS [osmotic-release oral syst]-Methylphenidate.

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Aug 2009

At a glance

  • Drugs Methylphenidate (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Sponsors Johnson & Johnson
  • Most Recent Events

    • 08 Jul 2009 Actual patient number (520) added as reported by ClinicalTrials.gov.
    • 22 Oct 2007 Status changed from in progress to completed.
    • 28 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top